Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Benedetta Conte

3PUBLICATIONS

57CO-AUTHORS

Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)

Featured researcher

Get your video featured.

Publish with JoVE

Featured researcher

Get your video featured.

Publish with JoVE

Publications (3)

Sort by Publication Date:

|Jan 22, 2026

Pembrolizumab and Paclitaxel in Patients with HR+/HER2- Breast Cancer with HER2-Enriched or Basal-like Subtypes.

Benedetta Conte, Fara Brasó-Maristany, Tomás Pascual

|Oct 27, 2023

SNP of Aromatase Predict Long-term Survival and Aromatase Inhibitor Toxicity in Patients with Early Breast Cancer: A Biomarker Analysis of the GIM4 and GIM5 Trials.

Benedetta Conte, Luca Boni, Giancarlo Bisagni

|Jan 06, 2022

Anthracycline, taxane, and trastuzumab-based neoadjuvant chemotherapy in HER2-positive early breast cancer: phase II trial.

Benedetta Conte, Filippo Montemurro, Alessia Levaggi

Pageof 1

Frequent Collaborators

2 joint publications

Aleix Prat

2 joint publications

Fara Brasó-Maristany

1 joint publications

Luca Boni

1 joint publications

Giancarlo Bisagni

1 joint publications

Antonio Durando

1 joint publications

Giovanni Sanna

1 joint publications

Stefania Gori

1 joint publications

Ornella Garrone

1 joint publications

Eva Ciruelos

1 joint publications

Sabino De Placido

Frequent Collaborators

2 joint publications

Aleix Prat

2 joint publications

Fara Brasó-Maristany

1 joint publications

Luca Boni

1 joint publications

Giancarlo Bisagni

Top Related Videos

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on : Dec 05, 2017

Evaluating the Effectiveness of Cancer Drug Sensitization <em>In Vitro</em> and <em>In Vivo</em>

Evaluating the Effectiveness of Cancer Drug Sensitization <em>In Vitro</em> and <em>In Vivo</em>

Published on : Feb 06, 2015

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on : Dec 11, 2017

See more related videos

Top Related Videos

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on : Dec 05, 2017

Evaluating the Effectiveness of Cancer Drug Sensitization <em>In Vitro</em> and <em>In Vivo</em>

Evaluating the Effectiveness of Cancer Drug Sensitization <em>In Vitro</em> and <em>In Vivo</em>

Published on : Feb 06, 2015

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on : Dec 11, 2017

See more related videos